Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZLD1039 is a potent, orally bioavailable EZH2 (Enhancer of Zeste Homolog 2) inhibitor with high selectivity. It demonstrates strong, concentration-dependent inhibition of both wild-type and mutant (Y641F and A677G) PRC2 (Polycomb Repressive Complex 2) enzymatic activities, exhibiting IC50 values of 5.6, 15, and 4.0 nM, respectively. Additionally, ZLD1039 effectively suppresses breast tumor growth and metastasis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 47.00 | |
5 mg | In stock | $ 113.00 | |
10 mg | In stock | $ 178.00 | |
25 mg | In stock | $ 397.00 | |
50 mg | In stock | $ 582.00 |
Description | ZLD1039 is a potent, orally bioavailable EZH2 (Enhancer of Zeste Homolog 2) inhibitor with high selectivity. It demonstrates strong, concentration-dependent inhibition of both wild-type and mutant (Y641F and A677G) PRC2 (Polycomb Repressive Complex 2) enzymatic activities, exhibiting IC50 values of 5.6, 15, and 4.0 nM, respectively. Additionally, ZLD1039 effectively suppresses breast tumor growth and metastasis. |
In vitro | ZLD1039 inhibited the H3K27me3 and H3K27me2 levels in MCF-7 (0.25~2 μM, 4 days) and MDA-MB-231 (1~4 μM, 4 days) cells in a dose-dependent manner[1]. |
Synonyms | ZLD-1039, ZLD 1039 |
Molecular Weight | 612.8 |
Formula | C36H48N6O3 |
CAS No. | 1826865-46-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Slightly soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZLD1039 1826865-46-6 Chromatin/Epigenetic Histone Methyltransferase ZLD-1039 ZLD 1039 inhibitor inhibit